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Background: Germline aryl hydrocarbon receptor-interacting protein (AIP) mutations occur in 15% of
familial isolated pituitary adenoma (FIPA) cases. To date, studies have focused on the identification of
such mutations in large international cohorts. Detailed genetic and clinical studies within AIP
mutation-positive families have been limited.
Aim: To undertake a comprehensive study of a large Brazilian FIPA kindred with an E174 frameshift
(E174fs) AIP mutation to assess clinical, hormonal, and radiological features in mutation carriers.
Methods: The kindred included 122 subjects across six generations; all underwent clinical
examination. Genetic studies were performed to identify E174fs mutation carriers. E174fs-positive
subjects underwent magnetic resonance imaging (MRI) and hormonal assessments.
Results: Of the ten germline AIP mutation carriers, three had pituitary tumors, while seven were
asymptomatic carriers. Three patients with pituitary tumors showed variability in terms of tumor
phenotype (two with acromegaly, one with prolactinoma, or mixed prolactin/GH-secreting tumor) and
age at diagnosis; both patients with acromegaly had poor responses to octreotide. Tumor AIP
immunohistochemistry from the operated patient showed decreased expression when compared with
normal tissue. Two adult subjects with normal MRI had elevated IGF-I in the absence of other causes.
A 2-year-old child with the E174fs mutation and a normal MRI had premature thelarche, ovarian
development, and advanced bone age in the absence of other underlying causes.
Conclusions: The penetrance of pituitary tumors in AIP mutation-positive adult subjects was
33.3%, while clinical/hormonal features were variable. The features noted in AIP-mutation
carriers in this kindred suggest that clinical characteristics of such carriers may extend beyond
pituitary tumors.
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Pituitary adenomas comprise w10% of intracranial
tumors and recent estimates suggest that clinically
apparent pituitary adenomas have a prevalence of w1
in 1000 individuals (1, 2). The pathophysiology of
pituitary adenomas is complex and a large number of
genetic and molecular defects have been identified. The
most relevant among these include mutations in the
Gsa and PTTG genes (3, 4). In general, pituitary
adenomas occur sporadically and the occurrence of
pituitary adenomas in a familial or hereditary setting is
rare; it is currently estimated that about 5% of pituitary
adenomas are familial as reviewed by Beckers & Daly in
this issue (5). Multiple endocrine neoplasia-I (MEN-I),n Journal of Endocrinologycaused by mutations in the MEN-I gene on chromosome
11q13 and Carney complex (CNC), due to mutations in
the PRKAR1A gene on chromosome 17q22, are well
recognized to cause familial pituitary adenomas (6, 7).
Isolated familial somatotropinoma (IFS) is a rare
condition separate from MEN-I and CNC that has been
reported in over 50 families (8, 9). Familial isolated
pituitary adenoma (FIPA), which comprises pituitary
adenomas of all phenotypes occurring in a family
setting, has been characterized in more than 90 families
over the past decade (9). Vierimaa et al. reported that
mutations in the aryl hydrocarbon receptor (AhR)-
interacting protein (AIP) gene were associated with
non-MEN-I, non-CNC familial pituitary adenomas (10).
Recently, Daly et al. reported that AIP mutations occurDOI: 10.1530/EJE-07-0533
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tumors in patients with AIP mutations are larger and
are diagnosed at a significantly younger age than in
FIPA patients without AIP mutations or in sporadic
tumors (11). Current evidence suggests that the
pituitary tumor phenotype of affected patients is
heterogeneous within and among families (10–12).
While somatotropinomas are the predominant finding
in association with AIP mutations, somatolactotrope
tumors, prolactinomas, and non-secreting adenomas
have all been described in the FIPA setting (11); a
patient with Cushing’s disease was also reported to have
an AIP mutation (12).
The studies mentioned above have focused on
identifying mutations in AIP in large international
cohorts of patients with sporadic or familial pituitary
tumors. While data on AIP status have been reported
retrospectively in previously described IFS families
(13, 14), neither these studies nor the international
cohort reports have presented detailed clinical, genetic,
hormonal, and pathological analysis of disease status in
families with AIP mutations. To this end, we undertook
a comprehensive study of 122 members of a Brazilian
FIPA kindred with an AIP mutation in order to
determine the clinical status of mutation carriers,
tumor characteristics (including immunohisto-
chemistry), and disease penetrance.Methods
Molecular genetic studies
Genomic DNA was isolated from the peripheral blood
of participating subjects. We used ensembl sequences
ENST00000279146, ENSG00000110711, and ENSP-
00000279146 to determine the sequence and
structure of AIP. The primers used for the analysis of
the AIP exonic and flanking intronic sequences are as
reported by Vierimaa et al. (10). For the PCR, each 25 ml
mixture contained 150 ng genomic DNA, 1 mM of each
primer, 1.5 mM MgCl2, 10 mM Tris–HCl buffer
(pH 8.3), 200 mM dNTPs, and 1.25 U FastStart Taq
polymerase (Roche). PCR conditions were as follows:
95 8C for 10 min followed by 30 cycles of 30 s at 95 8C,
30 s at 68 8C, and 20 s at 72 8C. PCR products were
sequenced using ABI3100 and BigDye Terminator v3.1
technology (Applied Biosystems, Lennik, Belgium).
An E174 frameshift (E174fsi; c.517_521delGAAGA;
GenBank accession number EF066503) AIP mutation
was noted in three members of the family with pituitary
adenomas; we have previously showed that the E174fs
mutation is not present in DNA from screened normal
volunteers (11).
The purpose of the study was explained and a
comprehensive series of interviews with members of
the kindred at various sites across Brazil were conducted
to construct a complete genealogical tree of 122www.eje-online.orgmembers across six generations. The kindred was
non-consanguineous. All consenting subjects provided
a full medical history and underwent a clinical
examination; these results were scrutinized for disease
expression or patterns of disease. Beginning with the
oldest living generations of the kindred, genetic studies
were performed (after obtaining informed consent) to
assess carrier status for the E174fs AIP mutation. In
mutation carriers, all relatives underwent molecular
genetic studies for AIP carrier status. Genetic studies
were performed only in those subjects that were possible
carriers of the E174fs AIP mutation based on the
genetic status of their parents. AIP mutation carriers
underwent further study involving non-enhanced
magnetic resonance imaging (MRI) of the brain
(2 mm cuts), static hormonal tests of the thyroid axis,
cortisol, growth hormone (GH), insulin-like growth
factor-I (IGF-I), and prolactin (PRL). All consenting AIP
mutation carriers underwent a 2-h oral glucose
tolerance test (OGTT) with measurement of GH.Immunohistochemistry
For determining the AIP immunohistochemistry of
pituitary tumor tissue from one operated patient,
paraffinized pituitary tumor sections were dewaxed in
xylene and rehydrated using a descending ethanol
series. Antigen retrieval was performed by microwave
boiling in citrate buffer pH 6.0 for two periods of 5 min
and one period of 3 min. Immunohistochemistry was
performed using a mouse anti-human AIP mAb at a
1:500 dilution (Novus Biological, DBA Italia s.r.l,
Segrate, Italy) and a multilink biotinylated antibody
and the avidin–biotin peroxidase system according to
the manufacturer’s instructions (LSABC kit, DAKO
Cytomation, Milan, Italy). For hormonal and tumor
marker immunohistochemistry using the streptavidin–
biotin system, the following dilutions of antibodies were
employed, anti-GH (polyclonal 1:2000), anti-PRL
(polyclonal 1:2000), p-53 (DO7 1:100), Ki-67 (Mib 1
1:100), and c-erb B2 (oncoprotein C 1:400). Reactions
were developed with diaminobenzidine and counter-
stained with hematoxylin.
The study was conducted in accordance with the
guidelines of the Declaration of Helsinki and the genetic
analysis was approved by the Ethics Committee of the
University of Lie`ge. All subjects or guardians provided
informed written consent for the investigations
performed.Results
Clinical features
Case 1 The index case, a male presented in 1997 at 17
years of age with a 3-year history of excessive linear
growth (188 cm at presentation; mother’s height
Variable features in family with AIP mutation 385EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007) 157154 cm, father’s height 160 cm), arthralgia, hyperhi-
drosis, weakness, headaches, and visual field impairment.
On examination, the patient exhibited physical features
typical of acromegaly, with soft tissue swelling, prog-
nathism, and enlarged extremities (shoe size 52). MRI
showed a pituitary macroadenoma measuring 36!45!
36 mm with compression of the optic chiasma and
bilateral cavernous sinus invasion (Fig. 1a). Basal GH
was 51 ng/ml and no suppression was seen during an
OGTT; the associated IGF-I level was 778 ng/dl (Table 1).
The patient underwent transsphenoidal surgery in 1998,
which reduced hormonal hypersecretion and improved
vision. GH and IGF-I were elevated postoperatively and
radiotherapy was performed in late 1998. Subcutaneous
intermittent octreotide (300 mg/day) was initiated but
tumor regrowth occurred by 2000. Despite increasing
medical therapy to octreotide LAR 30 mg/month and
cabergoline 2.0 g/week, the disease remained active and
the patient gained 5 cm in height from 1998 to 2003.
Late radiotherapy effects were seen from 2003 onwards
with a decrease in IGF-I (although they remain elevated),
and hypopituitarism (thyrotrope, corticotrope, andFigure 1Coronal and sagittal T1-weighted MRI taken at diagnosis in th
frameshift AIP mutation. (a) The index case presented at 17 years of
presented aged 25 with a 9!8 mm pituitary adenoma, and (c) the aun
pituitary macroadenoma. For (a), 3 mm cuts were used and for (b) angonadotrope axes) was diagnosed in 2006. MRI follow-
up in 2006 showed an empty sella.
Case 2 In 2002, the 25-year-old sister of the index case
presented with secondary amenorrhea, galactorrhea,
and headaches. On physical examination, there was
mild soft-tissue swelling of the face and hands, and no
visual field impairment. Hormonal assessment showed
elevated levels of PRL (148.5 ng/ml) and an increased
IGF-I (489 ng/dl). Basal GH secretion was 0.68 ng/ml,
which decreased but did not fully suppress (nadir level
0.38 ng/ml) during an OGTT. A 24-h GH profile showed
a mean GH concentration of 1.84 ng/ml. An MRI
revealed a pituitary adenoma of 9!8 mm in maximum
diameter (Fig. 1b). The patient was treated with
dopamine agonists, with adequate hormonal control
being achieved with a cabergoline dose of 2 g/week.
Subsequently, menses returned and headaches lessened,
but the patient has remained infertile despite normal
gonadal function. During follow-up, IGF-I levels were
noted to be intermittently above the normal range for
age and sex. The lack of absolute GH suppressionree family members with pituitary tumors in association with an E174
age with a large invasive pituitary macroadenoma, (b) his sister
t of the two other patients presented at age 35 with a non-invasive
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www.eje-online.orgcombined with the marked IGF-I elevation and
hyperprolactinemia suggest that a somatolactotrope
adenoma may be present in this case.
Case 3 The 35-year-old maternal aunt of cases 1 and 2
was first evaluated in 2005 on the advice of her nephew
(case 1). She had a 10-year history of worsening
arthralgia, hyperhidrosis, weakness, and headaches. Her
past medical history was relevant for three pregnancies
that all ended in late miscarriages at 20, 25, and 30
weeks’ gestation; no relevant structural or pathological
obstetric causes were found. Clinical examination
revealed typical facial features of acromegaly with
prognathism and pronounced soft-tissue swelling of the
lips and nose. No visual abnormalities were found and the
patient was of normal stature. Her basal GH was elevated
at 9.14 ng/ml, which failed to suppress during an OGTT
(nadir GH level 8.67 ng/ml). Her IGF-I was also elevated
at 610 ng/ml and her PRL was at 26.1 ng/ml. No other
hormonal abnormalities were present at diagnosis. An
MRI revealed a pituitary macroadenoma measuring
10!9!11 mm without evidence of extrasellar extension
or invasion (Fig. 1c). Following 7 months of treatment
with octreotide LAR at a dose of 30 mg/month, IGF-I
decreased but remained elevated at 378 ng/ml and no
tumor shrinkage was seen on MRI.Characteristics of mutation carriers
The genealogical tree for the family comprised 122
individuals and genetic studies identified seven
additional asymptomatic carriers of the E174fs
mutation across six generations; the mutation was
traced to the maternal grandfather of the index case
(Fig. 2). In the three cases with pituitary tumors, an
E174fs mutation in AIP was noted. The penetrance of
pituitary tumors among adult mutation carriers (nZ9)
in this FIPA family was 33.3%.
In the seven E174fs mutation carriers, clinical,
hormonal, and MRI studies were performed. No
pituitary adenomas were diagnosed in these seven
individuals. Four mutation carriers were entirely
hormonally and clinically normal. Two asymptomatic
mutation carriers were found to have IGF-I levels above
the normal range for their age and sex. In subject IIa,
the 71-year-old grandfather of the index case, an IGF-I
of 458 ng/ml (normal range for age and sex:
60–100 ng/ml) was noted, while subject IIIa, the
45-year-old mother of the cases 1 and 2, had an IGF-I
of 416 ng/ml (normal range: 101–267 ng/ml). The
elevated IGF-I levels were not associated with clinical
signs/symptoms and no concomitant conditions associ-
ated with elevated IGF-I were present. In both cases an
OGTT was normal (Table 1).
Figure 2 Genealogical tree of six generations of a family with an E174 frameshift AIP mutation. All members of the kindred underwent
medical assessments for signs and symptoms of pituitary or other diseases and the full genealogy was mapped. Consanguinity was ruled
out. Potential routes of inheritance of the mutated AIP were traced and molecular genetic studies were undertaken in targeted individuals to
assess whether the mutation had been passed to later generations.AIPmutation carriers underwent hormonal and radiological studies, and
all relatives of carriers were genotyped. Subjects marked with filled (black) symbols were the mutation-positive individuals with pituitary
tumors (cases 1, 2, and 3). Subjects marked with (C) were mutation carriers without clinical, hormonal, or radiological evidence of disease.
Subjects marked with (K) were genotyped as being wild-type homozygotes for AIP. Subjects marked with (?) declined genetic analysis but
were free from clinical evidence of pituitary or other illnesses. AIP mutation carriers with elevated IGF-I levels (subjects IIa and IIIa) are
shown (filled (black) upper right quadrant symbol); an infant girl with the E174fs AIP mutation and premature thelarche, ovarian
enlargement, and advanced bone age (subject Va) is shown (filled lower left quadrant symbol). Multiple partners/couplings are numbered
separately. Apart from the subjects noted above, clinical history and examination were normal in all other members of the kindred.
Variable features in family with AIP mutation 387EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007) 157A female infant (Va), a mutation carrier, was noted to
have premature thelarche at 1 year of age. After 1 year of
follow-up, breast development continued and reached
Tanner stage 3. At 23 months of age, she had a bone age
of 3 years. Pelvic ultrasound showed an enlarged right
ovary (1.8 cm3) with five visible follicles, while the left
ovary had a normal volume (0.7 cm3) and contained
three follicles; the uterus was normal in appearance and
volume (0.8 cm3). Hormonal evaluations showed a
follicle-stimulating hormone level of 1.3 mU/ml (normal
!1.6 mU/ml), a luteinizing hormone level of 0.1 mU/ml
(normal!0.6 mU/ml), an estradiol level of 11.9 pg/ml
(normal !8 pg/ml), and a PRL level of 8.5 ng/ml
(normal range 0.33–27.3 ng/ml). Gonadotrophin-
releasing hormone and OGTT tests were declined by
the parents at this time. An MRI revealed no pituitary,
hypothalamic, or other abnormalities. Clinical exami-
nation showed no features associated with known causes
of precocious puberty (e.g. no visible cafe´ au lait
spots suggestive of McCune-Albright syndrome) at last
follow-up in June 2007.
Further clinical evaluation of all ten individuals
bearing E174fs mutations revealed no symptomatology
or features suggestive of other potential AIP mutation-
associated disease in other tissues.Figure 3 Immunohistochemistry of pituitary tumor from index case.
(a) The tumor, which stained strongly positive for growth hormone
and prolactin (not shown) also had strong positive staining for c-erb.
(b) Immunohistochemistry of the pituitary tumor for AIP, showing
the reduced AIP staining seen in a region of tumor when compared
with a section of normal pituitary.Tumor immunohistochemistry
Only one of the three subjects with pituitary tumors
underwent surgery. Immunohistochemistry of the tumor
tissue from this patient showed strongly positive staining
(O50% of positive cells) for GH and PRL. Interestingly,
strong c-erb staining was also seen (Fig. 3a), while the
tumor was negative for Ki-67 and p53. AIP immuno-
histochemistry results are shown in Fig. 3b. Staining forwww.eje-online.org
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markedly lower than in the adjacent normal pituitary
fragment, where intense cytoplasmic staining was noted
in most cells. Faint nuclear staining was observed only in
a minority of normal pituitary cells.Discussion
The occurrence of pituitary tumors in a familial setting
accounts for 5% of pituitary tumors (5); most are due to
MEN-I, while CNC occurs very rarely (15). Recently,
acromegaly and MEN-I-like features were reported in
one family with a CDKN1B mutation, although such
mutations appear very rare (16–18). Germline
mutations of AIP occur in familial and sporadic
pituitary adenomas, although the latter are very
infrequent. In FIPA, AIP mutations account for half of
all cases of IFS, while 85% of families are negative for
AIP mutations indicating that other genes may be
involved in its pathogenesis (11).
The current report concerns a family that has not been
described in detail in the literature to date. With the
advent of molecular genetic testing for AIP, it was possible
to undertake an extensive prospective assessment of the
frequency of the occurrence of the E174fs mutation across
multiple generations. Overall, we found that ten individ-
uals bore the E174fs mutation, of which three had a
diagnosis of an isolated pituitary adenoma. As one of the
mutation carriers was an infant and it is usual to express
penetrance at a given age, we have elected to calculate
penetrance of pituitary tumors among adult mutation
carriers in this family. Thus, the penetrance of pituitary
tumors in this FIPA family was 33.3% (3/9). This
penetrance figure falls within the range of 25 toO85%
seen in other FIPA families withAIP mutations (Beckers &
Daly unpublished data). A similarly wide range for
penetrance has also been reported recently by another
international collaborative group (20). Taken together,
these data suggest that the occurrence of pituitary tumors
in patients with AIP mutations is not a low-penetrance
condition.
The phenotypic characteristics of the patients with
tumors in this family are varied, which appears to be a
feature of FIPA in general and of those with AIP mutations
in particular. On clinical findings, one patient had
prolactinoma and two had acromegaly. However,
hormonal data indicate that the patient with the
prolactinoma also had intermittently elevated IGF-I
secretion, suggesting the presence of a somatolactotrope
tumor. The index case with acromegaly also had combined
GH and PRL hypersecretion and his tumor stained strongly
positive for both hormones. Although both cases 1 and 3
had acromegaly, they differed significantly from each other.
Case 1 had much more aggressive disease in terms of an
early age at onset (17 vs 35 years), a larger tumor size and
much higher basal levels of GH secretion. Case 3 decided
not to undergo surgery at this time; therefore, it was notwww.eje-online.orgpossible to investigate pathological (immunohisto-
chemical) differences between the GH-secreting tumors in
both cases. Notably, both patients with acromegaly had
poor responses to octreotide therapy and required
combination treatment with a somatostatin analog and a
dopamine agonist. The underlying reason for this relative
octreotide resistance is unexplained, as is the more general
issue of why the same AIP mutation would cause different
pituitary tumor phenotypes in three closely related
individuals.
AIP immunohistochemistry has been previously
applied to pituitary tumor samples, although there are
few data regarding patterns of staining in normal tissue
and in different types of pituitary tumors. In the present
study, we used an mAb against human AIP, which
revealed cytoplasmic staining in only 30% of tumor cells
when compared with stronger and diffuse expression in
the adjacent normal pituitary fragment. This is in keeping
with the potential loss of expression of AIP protein in the
tumor tissue; however, results on loss of heterozygosity for
AIP in the paraffin tumor sample were equivocal. Indeed,
it is not known precisely how the E174fs mutation affects
AIP protein expression. The mutation would predict a
series of incorrect amino acids after position 174, followed
by a premature stop codon. Such a mutation would
abrogate the expression of the third tetratricopeptide
repeat domain (TPR) and carboxy-terminal residues that
are known to be crucial for interactions of AIP with the
AhR and the co-chaperone molecule heat shock protein
90 (hsp90) (11). Indeed, many of the mutations reported
to date predict protein changes that would affect the third
TPR domain and the carboxy terminal of AIP (10–14,
19). In vitro expression studies will be useful in helping to
determine whether the E174fs mutation is expressed as
protein or targeted for destruction via nonsense-mediated
mRNA decay or other pathways.
Detailed clinical and laboratory studies of the family
revealed no consistent features that were indicative of
potential AIP-related disease in other tissues, although
some endocrine findings are worth highlighting. In two
mutation carriers with normal MRI scans, elevated
levels of IGF-I were seen in the absence of abnormal GH
secretion on basal or strict dynamic testing. Addition-
ally, case 2 showed intermittent elevations in IGF-I
without abnormal GH secretion over the course of the
follow-up of her prolactinoma. Other causes of
increased IGF-I were ruled out in these cases, which
suggests that such elevations might be related to their
AIP mutation status, although a mechanistic expla-
nation remains difficult. It is not known whether
hormonal abnormalities could occur due to non-
tumoral pituitary hyperplasia in the setting of AIP
mutations, as frequently occurs in the pituitaries
of patients with CNC and McCune–Albright syndrome
(21, 22). Taken together with the differences in
pituitary tumor characteristics among the three cases
in this family, this clinical picture suggests wide
variability in disease expression among AIP mutation
Variable features in family with AIP mutation 389EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007) 157carriers. An explanation for this is lacking at this time,
although the effects of additional random somatic
mutations in the pituitary or elsewhere or the
modulating actions of other genes (normal or mutated)
must be considered.
Environmental factors are another important area of
great relevance to discussions of AIP and its potential role
in endocrine pathology. Current understanding of the role
played by AIP in pituitary cell function is still relatively
scanty. AIP has been studied extensively in toxicology,
where the effects of AIP in modulating the activity of its
receptor, AhR – the dioxin receptor – have received a great
deal of scrutiny. However, other effects of AIP on cellular
activity have been noted that may be equally relevant to
tumorigenic potential. The phosphodiesterases, PDE4A5
and PDE2A, survivin, and translocase of outer
mitochondrial membrane 20 (TOM20) are all defined
targets for AIP and could undergo dysregulation in the
setting of AIP mutations, potentially leading to enhanced
cell growth and survival (23–27). Fundamental work on
the role of AIP mutations in abnormally modulating cell
signaling remains to be performed, and the pathway by
which pituitary tumors occur in patients with germline
AIP mutations remains speculative.
In terms of the potential involvement of mutated AIP in
the pathogenesis of the premature thelarche and
abnormal ovarian/bone development in subject Va,
AhR-related pathways are known to be involved in
gonadotropic axis development (28, 29). AhR-mediated
gene transcription is modulated via direct recruitment of
estrogen receptor-a, which links estradiol activity to AhR–
dioxin-mediated signaling (30, 31). This and other
associated pathways (e.g. via hsp70 (32, 33)) are thought
to play an important role in the physiology of sexual
development at a cellular level in the pituitary. Exposure to
dioxin and other environmental toxins during embryonic
development can have estrogenic effects, leading to
alterations in cellular signaling, biochemical activity,
and reproductive function (34–36). Alterations in the
AhR pathway are associated with reproductive disorders
in animal models (37) and even in humans (38, 39).
Intriguingly, animal data suggest that a connection may
exist among environmental estrogenic disruptors, AhR
pathway signaling and expression of GH, and PRL mRNA
in the pituitary, an effect that may be modulated at the
level of Pit1 (40–42). While no definitive link betweenAIP
status and the clinical phenotype of subject Va can be
made, it is worth considering given the overlaps between
AhR pathways, early life hormonal exposure, and
subsequent reproductive physiology (43). There was no
known history of abnormal estrogenic exposure in the
child while in utero or subsequently and no pathological
changes of the pituitary or hypothalamus were apparent
on MRI. Ongoing follow-up will assess whether the breast,
ovarian, and bone changes progress and if abnormalities
of the gonadotropic axis become apparent.
In conclusion, this is the first study to examine in
depth the clinical, hormonal, and radiological featuresof a large FIPA kindred with three patients with
pituitary adenomas (acromegaly and prolactinoma)
associated with mutations in AIP. Among seven
asymptomatic mutation carriers, elevations in IGF-I
were seen in two adult individuals, while an infant girl
presented a progressing pattern of sexual precocity.
These results suggest that the same AIP mutation can
be associated with a variable phenotype of pituitary
tumors among related family members (as suggested
previously (11)) and raises the possibility of the
involvement of non-tumoral pituitary pathology in
mutation carriers. The field of AIP research in the
setting of pituitary endocrinology is at an early stage
and fundamental data on mutated AIP protein
expression and function from in vitro and animal studies
is lacking at this time. Before firm conclusions can be
drawn regarding clinical disease characteristics related
to AIP mutations, the analysis of data from larger
cohorts of affected patients will be required.Acknowledgements
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